Gyeonggawon Provides Regulatory Consultation for Advanced Biopharmaceuticals... Supports R&D and Commercialization
The Gyeonggi-do Economic Science Promotion Agency held a consultation event related to advanced biopharmaceutical regulations.
On the 8th, the agency announced that it hosted the "Advanced Biopharmaceutical-Regulatory Science Consultation Day" at the Gyeonggi-do Bio Center in Suwon Gwanggyo Techno Valley, co-organized with the National Institute of Food and Drug Safety Evaluation (NIFDS) and the Osong Advanced Medical Industry Promotion Foundation.
At the event, seven companies in the province with demand for regulatory consultations related to advanced biopharmaceuticals participated, conducting consultations divided into two categories: quality evaluation and clinical trials and product approval regarding safety and efficacy.
Advanced biopharmaceuticals refer to medicines including cell therapies, gene therapies, tissue engineering products, and advanced bio-convergence products under the "Act on Safety and Support of Advanced Regenerative Medicine and Advanced Biopharmaceuticals." Regulatory science is a specialized field that presents scientific evidence for regulatory systems such as food and drug approvals.
The "Advanced Biopharmaceutical-Regulatory Science Consultation Day" was organized to actively support research and development and commercialization through expert technical consultations related to clinical trials and product approval reviews of advanced biopharmaceuticals.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
Kang Seong-cheon, head of the Gyeonggi-do Economic Science Promotion Agency, emphasized, "The bioindustry is a core business that will be responsible for Korea's future growth engines. Among them, advanced regenerative medicine and advanced biopharmaceuticals have exceptional technological and research value as they can provide fundamental treatments for rare and intractable diseases." He added, "We will do our best to actively utilize the infrastructure and technological capabilities possessed by the agency to support regulatory science and approvals for advanced biopharmaceutical companies in the province, serving as a catalyst for the development of the domestic bioindustry."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
